ContractLetter Agreement • April 6th, 2021 • Petros Pharmaceuticals, Inc. • Pharmaceutical preparations
This letter agreement (this “Second Letter Agreement”) is being entered into as of March 31, 2021 (the "Effective Date") by and between Metuchen Pharmaceuticals LLC ("METUCHEN") and Hybrid Medical LLC ("HYBRID") (referred to herein collectively as the "Parties") to amend the License Agreement entered into between the Parties on March 24, 2020 pursuant to Section 12.11 thereof, as amended by that certain letter agreement (the “First Letter Agreement”) dated September 24, 2020 between METUCHEN and HYBRID (as amended by the First Letter Agreement, the "License Agreement"). Except as specifically provided herein, nothing in this Second Letter Agreement is intended to, nor shall it, modify the License Agreement in any manner, including, but not limited to, the Milestone Payments as set forth in Section 4.2 of the License Agreement. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the License Agreement.
